In view of the proposed role of MTAP deficiency as a predictor of poor response to CPIs, we made use of the tumor microenvironment data from earlier studies to evaluate the possible interactions of MTAP deficiency with antitumor immunity [29]. This evidence concerns the gene MTAP and neoplasm.